| Immunologic Deficiency Syndromes |
STAR, NCT03037372: Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial |
|
|
| Not yet recruiting | 3 | 320 | NA | ART, Atorvastatin, Atovastatin adjunct therapy, ART, Rosuvastatin, Rosuvastatin adjunct therapy, ART, No statin, No statin adjunct therapy, Healthy-HIV-negative, HIV-negative controls | Makerere University, University of Oxford, Case Western Reserve University | HIV Infection | 06/22 | 12/22 | | |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
NCT00010348: Study of Total Body Irradiation in Combination With Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation Followed By Cyclosporine and Mycophenolate Mofetil in High Risk-Patients With Human Immunodeficiency Virus-1 |
|
|
| Recruiting | 2 | 20 | US | Cyclosporine, Mycophenolate mofetil, Total body irradiation and stem cell or bone marrow transplantation | Fred Hutchinson Cancer Research Center | HIV Infections | 12/10 | 12/15 | | |
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program |
|
|
| No Longer Available | N/A | | US | Atazanavir (BMS-232632) | Bristol-Myers Squibb | HIV Infections | | 07/03 | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00547235: Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection |
|
|
| No Longer Available | N/A | | US | therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, total-body irradiation | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Infection, Precancerous/Nonmalignant Condition | 12/12 | | | |
NCT02028819: Compassionate Use of Ibalizumab for the Treatment of HIV Infection |
|
|
| No Longer Available | N/A | | US | Dolutegravir Sodium Monohydrate, TIVICAY, Ibalizumab, TMB-355 | University of Colorado, Denver | Human Immunodeficiency Virus (HIV) | 02/14 | 02/14 | | |
NCT00975546: HIV-discordant Couple Intrauterine Insemination |
|
|
| No Longer Available | N/A | | US | Sperm washing and testing for HIV contamination, Intrauterine Insemination | University of Missouri-Columbia | Infertility, HIV Infections | | | | |
NCT02712671: Testing for Tuberculosis in the United Kingdom HIV Infected Population |
|
|
| Active, not recruiting | N/A | 300 | Europe | Chest radiograph, Chest X ray, Blood interferon gamma release assay, Blood IGRA, TSpot.TB, Tuberculin skin testing (TST), TST, Mantoux test, Sputum induction for mycobacterial microscopy and culture, Mycobacterium tuberculosis polymerase chain reaction testing, TB PCR, GeneXpert MTB/RIF, Spirometry, Lung function | University College, London | HIV, Latent Tuberculosis | 02/16 | 09/24 | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
| No Longer Available | N/A | | US | CliniMACs | University of Miami, Jackson Health System | x Linked Combined Immunodeficiency | | | | |
NCT02680652: Improving the Diagnosis of Common Variable Immune Deficiency |
|
|
| Not yet recruiting | N/A | 150 | US | | Stanford University | Common Variable Immune Deficiency (CVID) | 01/18 | 07/18 | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |
NCT03010332: Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease |
|
|
| No Longer Available | N/A | | NA | Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs), ATA230 | Atara Biotherapeutics | CMV Viremia, CMV Disease | | | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study |
|
|
| Recruiting | N/A | 2017 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 01/25 | 01/25 | | |
NCT02149004: German Centre for Infection Research HIV Translational Platform |
|
|
| Recruiting | N/A | 10000 | Europe | | University Hospital of Cologne, German Center for Infection Research, German Federal Ministry of Education and Research | HIV | 01/35 | 01/35 | | |